EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

Population Pharmacokinetics of Oral-Based Administration of Cannabidiol in Healthy Adults: Implications for Drug Development

Hayley B Schultz iD, Adele Hosseini, Andrew J McLachlan, Stephanie E Reuter

Cannabis & Cannabinoid Research · 01.10.2023 · 8 (5) · 877-886

DOI: 10.1089/can.2021.0202 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cannabis & Cannabinoid Research, online erschienen am 09.10.2023. Verfasst von Hayley B Schultz und 3 weiteren Autor:innen. Beteiligte Einrichtung: UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Cannabidiol. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Cannabidiol (CBD) is increasingly being studied as a therapeutic option for a range of health conditions; however, the pharmacokinetics of CBD is not well understood. This study characterized CBD pharmacokinetics in healthy adults using a population pharmacokinetic approach, informing drug development of oral-based dose forms of CBD. Materials and Methods: CBD concentration-time data were obtained from a phase I, randomized, open-label, four-way crossover study ( n =12) and modeled using Phoenix NLME. Monte Carlo simulations were conducted to estimate CBD exposure with chronic dosing as intended for clinical use (50 mg b.i.d.).

Results

A three-compartment pharmacokinetic model with a chain of absorption transit compartments and first-order elimination most adequately described CBD pharmacokinetics. Substantial variability in population pharmacokinetic parameters was identified (up to 60%CV), which could not be accounted for by any covariates. Simulations indicated a 3.6-fold difference in drug exposure at steady state with multiple dosing (AUC τ 95% prediction interval: 65.5–138 ng·h/mL), and variability in the time to reach steady state, which was predicted to be up to ∼3 weeks in some individuals (95% prediction interval: 18.6–297 h).

Conclusions

The findings of this study have important implications for drug development. The lack of a clear dose-response relationship, due to large pharmacokinetic variability, indicates that a one-size-fits-all approach to CBD dosing may not be feasible, at least with current dosing approaches. Furthermore, an extended time to reach steady state means that the full effect of a selected dose level is not truly observed for some time and requires careful consideration in trial design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolHumansAdultCross-Over StudiesAdministration, OralDrug DevelopmentHealthy Volunteers

Stichwörter der Autor:innen

absorptioncannabidiolclinicalmodelingoralpharmacokinetics

Substanzen

Cannabidiol

Autor:innen und Institutionen

  • UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
  • Bod Australia Pty Ltd., Sydney, New South Wales, Australia.
  • Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Hayley B Schultz

Zitieren

APA

Schultz, H. B., Hosseini, A., McLachlan, A. J., & Reuter, S. E. (2023). Population Pharmacokinetics of Oral-Based Administration of Cannabidiol in Healthy Adults: Implications for Drug Development. Cannabis & Cannabinoid Research, 8(5), 877-886. https://doi.org/10.1089/can.2021.0202

Vancouver

Schultz HB, Hosseini A, McLachlan AJ, Reuter SE. Population Pharmacokinetics of Oral-Based Administration of Cannabidiol in Healthy Adults: Implications for Drug Development. Cannabis & Cannabinoid Research. 2023;8(5):877-886. doi:10.1089/can.2021.0202

BibTeX
@article{Schultz2023,
  author = {Schultz, Hayley B and Hosseini, Adele and McLachlan, Andrew J and Reuter, Stephanie E},
  title = {Population Pharmacokinetics of Oral-Based Administration of Cannabidiol in Healthy Adults: Implications for Drug Development},
  journal = {Cannabis & Cannabinoid Research},
  year = {2023},
  volume = {8},
  number = {5},
  pages = {877--886},
  doi = {10.1089/can.2021.0202}
}
Kostenlos starten →